R&D
Partner Content
2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy S...
Exciting results are expected this year, from multiple mid and late stage clinical trials and involving a broad array of adenosine drugs including CD73, CD39 and A2AR!
